The only peptide approved for treating sexual dysfunction in both men and women. PT-141 (Bremelanotide) works centrally on melanocortin receptors in the brain to naturally enhance libido, arousal, and sexual satisfaction — without the cardiovascular effects of PDE5 inhibitors.
PT-141, also known as Bremelanotide, is a synthetic peptide derived from Melanotan II. It is the first and only FDA-approved medication that works on the central nervous system — specifically the melanocortin system — to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use for men has shown strong results.
Unlike Viagra or Cialis which work on blood flow, PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus — the brain's sexual desire center. This triggers genuine desire and arousal at the neurological level rather than simply increasing blood flow to the genitals.
PT-141 is typically administered as a subcutaneous injection 30–60 minutes before desired effect. Most patients report increased desire and arousal within 45 minutes. Effects can last 4–12 hours. Your provider will guide you on dosing based on your health profile.
Important Medical Disclaimer: PT-141 (Bremelanotide) is a prescription peptide and must be prescribed by a licensed provider after a medical evaluation. This product requires a valid prescription from a licensed healthcare provider. Guppy Meds connects patients with independent licensed providers who make all prescribing decisions. This is not a substitute for professional medical advice. Individual results vary. All compounded medications are prepared by a licensed 503(a) compounding pharmacy. These statements have not been evaluated by the Food and Drug Administration.
Real experiences from real patients who have transformed their health with Guppy Meds.
“PT-141 has done more for my relationship and confidence than anything I have tried before. My provider at Guppy Meds handled the consultation with complete professionalism and zero judgment.”
“The discreet packaging and the fact that no one had to know about my consultation made all the difference. Results were noticeable within the first week of use.”
“I appreciated that my provider took time to discuss how PT-141 works centrally rather than just peripherally. That distinction matters, and their clinical depth impressed me.”
We hold ourselves to the highest standards of clinical quality, privacy, and patient care.
PT-141 (bremelanotide) works centrally through the nervous system — not peripherally — making it unique among sexual health treatments.
PT-141 binds to melanocortin receptors (MC3R and MC4R) in the hypothalamus — the brain's center for sexual arousal. This central mechanism means it works even in patients unresponsive to PDE5 inhibitors.
Melanocortin receptor activation triggers dopamine release in the limbic system, increasing feelings of desire and motivation. This makes PT-141 effective for both physical and psychological components of sexual dysfunction.
The central signaling cascade promotes increased blood flow, genital sensitivity, and arousal in both men and women. Onset typically occurs within 30–45 minutes of injection and lasts 6–12 hours.
PT-141 has been studied in both male and female sexual dysfunction with notable results.
A Phase 2b placebo-controlled trial of men with erectile dysfunction found that 59% of PT-141 subjects reported successful sexual activity, versus 25% in the placebo group. Notably effective in men with psychogenic ED unresponsive to sildenafil.
In premenopausal women with hypoactive sexual desire disorder, bremelanotide significantly increased satisfying sexual events and reduced personal distress scores compared to placebo in Phase 3 trials.
Most patients report a predictable progression of results as they continue therapy.
Onset within 30–45 minutes. Most patients experience mild flushing and increased arousal within the first use. Some mild nausea is possible at higher doses.
Your provider may adjust dosing based on your response. Side effects like nausea typically diminish as the body acclimates and the dose is dialed in.
By the end of the first month most patients report predictable, reliable arousal responses. Psychological confidence often improves alongside physical effects.
Patients on ongoing therapy report sustained improvements in desire, satisfaction, and relationship wellbeing. Provider check-ins ensure dosing remains optimized.
The information provided on this website is for educational and informational purposes only and is not intended as medical advice. All treatments require a valid prescription from a licensed medical provider. Individual results may vary. Consult your healthcare provider before beginning any new treatment protocol.